Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India

被引：0
|
作者：
Varughese, V. J. [1 ]
Joseph, S. [1 ]
Sirohi, B. [1 ]
Raut, N. [1 ]
Mathew, A. [1 ]
机构：
[1] Mosc Med Coll, Oncol, Kolenchery, Ernakulam, India
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
EGFR HER2 Exon 20 mutation; poziotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P50.08
引用
收藏
页码：S1117 / S1117
页数：1
相关论文
共 50 条
  • [1] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [2] A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
    Cognigni, Valeria
    Capelletto, Enrica
    Bordi, Paola
    Pavese, Valeria
    Carfi, Federica Maria
    Gelsomino, Francesco
    De Giglio, Andrea
    Chiari, Rita
    Minari, Roberta
    Ambrosini, Enrico
    Percesepe, Antonio
    Giachino, Daniela
    Bironzo, Paolo
    Tiseo, Marcello
    [J]. TUMORI JOURNAL, 2024,
  • [3] HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
    Zhang, Xinyong
    Lv, Jialin
    Wu, Yuhua
    Qin, Na
    Ma, Li
    Li, Xi
    Nong, Jingying
    Zhang, Hui
    Zhang, Quan
    Yang, Xinjie
    Shi, Huibo
    Wang, Jinghui
    Zhang, Shucai
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] EGFR exon 20 insertion mutation in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Takada, Minoru
    Kawahara, Masaaki
    Kitahara, Naoto
    Tanaka, Hisaichi
    Okumura, Meinoshin
    Matsumura, Akihide
    Luchi, Keiji
    Kawaguchi, Tomoya
    Kawano, Osamu
    Yukiue, Haruhiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    [J]. LUNG CANCER, 2007, 58 (03) : 324 - 328
  • [5] Development of treatment for HER2 or EGFR exon 20 insertion mutation-driven NSCLC
    Ninomiya, Kiichiro
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S444 - S444
  • [6] Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
    Prelaj, Arsela
    Bottiglieri, Achille
    Proto, Claudia
    Lo Russo, Giuseppe
    Signorelli, Diego
    Ferrara, Roberto
    Galli, Giulia
    De Toma, Alessandro
    Viscardi, Giuseppe
    Brambilla, Marta
    Lobefaro, Riccardo
    Nichetti, Federico
    Manglaviti, Sara
    Occhipinti, Mario
    Labianca, Alice
    Ganzinelli, Monica
    Gallucci, Rosaria
    Zilembo, Nicoletta
    Greco, Gabriella Francesca
    Torri, Valter
    de Braud, Filippo
    Garassino, Marina C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 149 : 235 - 248
  • [7] Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
    Metro, Giulio
    De Giglio, Andrea
    Ricciuti, Biagio
    Siringo, Marco
    Marinelli, Daniele
    Gelibter, Alain
    Pecci, Federica
    Berardi, Rossana
    Cantini, Luca
    Di Federico, Alessandro
    Andrini, Elisa
    Mosca, Mirta
    Lamberti, Giuseppe
    Brambilla, Marta
    Mountzios, Giannis
    [J]. DRUGS IN CONTEXT, 2022, 11
  • [8] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Danielle Brazel
    Gianna Kroening
    Misako Nagasaka
    [J]. BioDrugs, 2022, 36 : 717 - 729
  • [9] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Brazel, Danielle
    Kroening, Gianna
    Nagasaka, Misako
    [J]. BIODRUGS, 2022, 36 (06) : 717 - 729
  • [10] First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma
    Luan, Tao
    Lin, Xinqing
    Xie, Xiaohong
    Yang, Gang
    Wang, Shuaiying
    Hao, Jianqing
    Zhou, Chengzhi
    [J]. ANTI-CANCER DRUGS, 2024, 35 (08) : 757 - 760
12345